Literature DB >> 18434385

TGFbeta-induced RhoA activation and fibronectin production in mesangial cells require caveolae.

Fangfang Peng1, Baifang Zhang, Dongcheng Wu, Alistair J Ingram, Bo Gao, Joan C Krepinsky.   

Abstract

Glomerular sclerosis of diverse etiologies is characterized by mesangial matrix accumulation, with transforming growth factor-beta (TGFbeta) an important pathogenic factor. The GTPase RhoA mediates TGFbeta-induced matrix accumulation in some settings. Here we study the role of the membrane microdomain caveolae in TGFbeta-induced RhoA activation and fibronectin upregulation in mesangial cells (MC). In primary rat MC, TGFbeta1 time dependently increased RhoA and downstream Rho kinase activation. Rho pathway inhibition blocked TGFbeta1-induced upregulation of fibronectin transcript and protein. TGFbeta1-induced RhoA activation was prevented by disrupting caveolae with cholesterol depletion and rescued by cholesterol repletion. Compared with wild types, RhoA/Rho kinase activation was absent in MC lacking caveolae. Reexpression of caveolin-1 (and caveolae) restored these responses. Phosphorylation of caveolin-1 on Y14, effected by Src kinases, has been implicated in signaling responses. Overexpression of nonphosphorylatable caveolin-1 Y14A prevented TGFbeta1-induced RhoA activation. TGFbeta1 also activated Src, and its inhibition blocked RhoA activation. Furthermore, TGFbeta1 led to association of RhoA and caveolin-1. This was prevented by Src or TGFbeta receptor I inhibition, and by caveolin-1 Y14A overexpression. Last, fibronectin upregulation by TGFbeta1 was blocked by Src inhibition, not seen in caveolin-1 knockout MC, and restored by caveolin-1 reexpression in the latter. TGFbeta1-induced collagen I accumulation also required caveolae. TGFbeta1-mediated Smad2/3 activation, however, did not require caveolae. We conclude that RhoA/Rho kinase mediates TGFbeta-induced fibronectin upregulation. This requires caveolae and caveolin-1 interaction with RhoA. Interference with caveolin/caveolae or RhoA signaling thus represents a potential target for the treatment of fibrotic renal disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434385      PMCID: PMC2494513          DOI: 10.1152/ajprenal.00419.2007

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  65 in total

Review 1.  Transcriptional control by the TGF-beta/Smad signaling system.

Authors:  J Massagué; D Wotton
Journal:  EMBO J       Date:  2000-04-17       Impact factor: 11.598

2.  Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor beta-related signaling.

Authors:  C Sirard; S Kim; C Mirtsos; P Tadich; P A Hoodless; A Itié; R Maxson; J L Wrana; T W Mak
Journal:  J Biol Chem       Date:  2000-01-21       Impact factor: 5.157

3.  Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor.

Authors:  B Razani; X L Zhang; M Bitzer; G von Gersdorff; E P Böttinger; M P Lisanti
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

4.  ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling.

Authors:  Y Sano; J Harada; S Tashiro; R Gotoh-Mandeville; T Maekawa; S Ishii
Journal:  J Biol Chem       Date:  1999-03-26       Impact factor: 5.157

Review 5.  Smads as transcriptional co-modulators.

Authors:  L Attisano; J L Wrana
Journal:  Curr Opin Cell Biol       Date:  2000-04       Impact factor: 8.382

6.  Synergistic cooperation between Sp1 and Smad3/Smad4 mediates transforming growth factor beta1 stimulation of alpha 2(I)-collagen (COL1A2) transcription.

Authors:  W Zhang; J Ou; Y Inagaki; P Greenwel; F Ramirez
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

7.  Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette.

Authors:  H Lee; D Volonte; F Galbiati; P Iyengar; D M Lublin; D B Bregman; M T Wilson; R Campos-Gonzalez; B Bouzahzah; R G Pestell; P E Scherer; M P Lisanti
Journal:  Mol Endocrinol       Date:  2000-11

8.  Caveolae in mesangial cells and caveolin expression in mesangial proliferative glomerulonephritis.

Authors:  O Tamai; N Oka; T Kikuchi; Y Koda; M Soejima; Y Wada; M Fujisawa; K Tamaki; H Kawachi; F Shimizu; H Kimura; T Imaizumi; S Okuda
Journal:  Kidney Int       Date:  2001-02       Impact factor: 10.612

9.  Epidermal growth factor-stimulated tyrosine phosphorylation of caveolin-1. Enhanced caveolin-1 tyrosine phosphorylation following aberrant epidermal growth factor receptor status.

Authors:  Y N Kim; G J Wiepz; A G Guadarrama; P J Bertics
Journal:  J Biol Chem       Date:  2000-03-17       Impact factor: 5.157

10.  Central role for Rho in TGF-beta1-induced alpha-smooth muscle actin expression during epithelial-mesenchymal transition.

Authors:  Andras Masszi; Caterina Di Ciano; Gábor Sirokmány; William T Arthur; Ori D Rotstein; Jiaxu Wang; Christopher A G McCulloch; László Rosivall; István Mucsi; András Kapus
Journal:  Am J Physiol Renal Physiol       Date:  2002-12-27
View more
  34 in total

1.  Blocking VEGF/Caveolin-1 signaling contributes to renal protection of fasudil in streptozotocin-induced diabetic rats.

Authors:  Jing Jin; Chao Peng; Su-zhen Wu; Hong-min Chen; Bai-fang Zhang
Journal:  Acta Pharmacol Sin       Date:  2015-05-04       Impact factor: 6.150

2.  Caveolin-1 Regulates Atherogenesis by Attenuating Low-Density Lipoprotein Transcytosis and Vascular Inflammation Independently of Endothelial Nitric Oxide Synthase Activation.

Authors:  Cristina M Ramírez; Xinbo Zhang; Chirosree Bandyopadhyay; Noemi Rotllan; Michael G Sugiyama; Binod Aryal; Xinran Liu; Shun He; Jan R Kraehling; Victoria Ulrich; Chin Sheng Lin; Heino Velazquez; Miguel A Lasunción; Guangxin Li; Yajaira Suárez; George Tellides; Filip K Swirski; Warren L Lee; Martin A Schwartz; William C Sessa; Carlos Fernández-Hernando
Journal:  Circulation       Date:  2019-06-03       Impact factor: 29.690

3.  Low-dose endothelial monocyte-activating polypeptide-ii increases permeability of blood-tumor barrier by caveolae-mediated transcellular pathway.

Authors:  Zhen Li; Yun-hui Liu; Yi-xue Xue; Li-bo Liu; Ping Wang
Journal:  J Mol Neurosci       Date:  2013-10-25       Impact factor: 3.444

Review 4.  Transforming Growth Factor β1 Function in Airway Remodeling and Hyperresponsiveness. The Missing Link?

Authors:  Christie A Ojiaku; Edwin J Yoo; Reynold A Panettieri
Journal:  Am J Respir Cell Mol Biol       Date:  2017-04       Impact factor: 6.914

Review 5.  Caveolin-1 in the Pathogenesis of Diabetic Nephropathy: Potential Therapeutic Target?

Authors:  Richard Van Krieken; Joan C Krepinsky
Journal:  Curr Diab Rep       Date:  2017-03       Impact factor: 4.810

6.  Caveolin-1 is involved in reactive oxygen species-induced SHP-2 activation in astrocytes.

Authors:  Ji Hee Yun; Soo Jung Park; Ara Jo; Jihee Lee Kang; Ilo Jou; Jung Soo Park; Youn Hee Choi
Journal:  Exp Mol Med       Date:  2011-12-31       Impact factor: 8.718

Review 7.  Membrane rafts and caveolae in cardiovascular signaling.

Authors:  Paul A Insel; Hemal H Patel
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-01       Impact factor: 2.894

8.  Connexin45 regulates endothelial-induced mesenchymal cell differentiation toward a mural cell phenotype.

Authors:  Jennifer S Fang; Cuiping Dai; David T Kurjiaka; Janis M Burt; Karen K Hirschi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12-06       Impact factor: 8.311

9.  Role of km23-1 in RhoA/actin-based cell migration.

Authors:  Qunyan Jin; Nageswara R Pulipati; Weidong Zhou; Cory M Staub; Lance A Liotta; Kathleen M Mulder
Journal:  Biochem Biophys Res Commun       Date:  2012-10-15       Impact factor: 3.575

10.  Mechanistic basis of Rho GTPase-induced extracellular matrix synthesis in trabecular meshwork cells.

Authors:  Padmanabhan P Pattabiraman; Ponugoti Vasantha Rao
Journal:  Am J Physiol Cell Physiol       Date:  2009-11-25       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.